Internal radiotherapy of painful bone metastases

Liepe, Knut; Kotzerke, J.

doi:10.1016/j.ymeth.2011.07.001

Cited by 29 publications

(15 citation statements)

References 193 publications

(370 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…153 Sm-EDTMP showed a pain relief rate in 62–84% of patients with metastatic bone pain. These studies are also summarized in reviews [ 6 – 8 ]. Meanwhile, in a study of comparison between the effects of the 89 SrCl 2 and 153 Sm-EDTMP to patients with bone metastases, there was no statistical difference in response rates [ 12 ].…”

Section: Introductionmentioning

confidence: 99%

Well-Designed Bone-Seeking Radiolabeled Compounds for Diagnosis and Therapy of Bone Metastases

Ogawa

Ishizaki

2015

BioMed Research International

View full text Add to dashboard Cite

Bone-seeking radiopharmaceuticals are frequently used as diagnostic agents in nuclear medicine, because they can detect bone disorders before anatomical changes occur. Furthermore, their effectiveness in the palliation of metastatic bone cancer pain has been demonstrated in the clinical setting. With the aim of developing superior bone-seeking radiopharmaceuticals, many compounds have been designed, prepared, and evaluated. Here, several well-designed bone-seeking compounds used for diagnostic and therapeutic use, having the concept of radiometal complexes conjugated to carrier molecules to bone, are reviewed.

show abstract

Section: Introductionmentioning

confidence: 99%

Well-Designed Bone-Seeking Radiolabeled Compounds for Diagnosis and Therapy of Bone Metastases

Ogawa

Ishizaki

2015

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…Despite numerous studies attempting to better understand bone metastasis pathophysiology, there are as yet no established and efficient clinical methods for their cure and/or their prevention. Currently, medical management of bone metastases is based on local approaches (i.e., surgery, radiation therapy) or systemic strategies such as molecular targeted therapies [ 66 , 69 ].…”

Section: Bone Metastasis Treatmentsmentioning

confidence: 99%

Understanding the Progression of Bone Metastases to Identify Novel Therapeutic Targets

Schmid-Alliana

Schmid-Antomarchi

Al-Sahlanee

et al. 2018

IJMS

View full text Add to dashboard Cite

Bone is one of the most preferential target site for cancer metastases, particularly for prostate, breast, kidney, lung and thyroid primary tumours. Indeed, numerous chemical signals and growth factors produced by the bone microenvironment constitute factors promoting cancer cell invasion and aggression. After reviewing the different theories proposed to provide mechanism for metastatic progression, we report on the gene expression profile of bone-seeking cancer cells. We also discuss the cross-talk between the bone microenvironment and invading cells, which impacts on the tumour actions on surrounding bone tissue. Lastly, we detail therapies for bone metastases. Due to poor prognosis for patients, the strategies mainly aim at reducing the impact of skeletal-related events on patients’ quality of life. However, recent advances have led to a better understanding of molecular mechanisms underlying bone metastases progression, and therefore of novel therapeutic targets.

show abstract

“…Currently, in many Nuclear Medicine centres in addition to radioiodine therapy for thyroid cancer, radionuclide therapies such as radioembolisation of liver tumours and radiopeptide- and radioimmunotherapies for neuroendocrine tumours and lymphomas, as well as treatment of painful bone metastases with different radionuclides, are being performed [ 1 – 5 ]. Most importantly, radioligand therapy for metastatic prostate cancer with Lu-177-PSMA, which has been established in some centres, shows remarkable treatment response and prolongation of overall survival in patients who do not have any other treatment options [ 6 – 10 ]; this further demonstrates the increasing importance of our specialty.…”

Section: Dear Editormentioning

confidence: 99%

It is time to move forward into the era of Theranostics

Ahmadzadehfar

Essler

2018

EJNMMI Res

View full text Add to dashboard Cite

Radionuclide therapy, which until 15 years ago included only a few approved therapies, is gaining importance in the treatment of various malignancies. The future of oncology will not be limited to surgery, chemo-, antibody therapies or external radiation; it will include targeted therapy with radionuclides, which will become the standard of care for a variety of malignant diseases in combination or as an alternative to other therapies. Therefore there is a need to train Nuclear Oncologists, who are able to approach oncological diseases, promote development of radiopharmacy, understand the biology of radionuclide treatment, apply radionuclide treatments and be able to use molecular imaging such as PET/CT and SPECT/CT for treatment planning and dosimetry.

show abstract

Internal radiotherapy of painful bone metastases

Cited by 29 publications

References 193 publications

Well-Designed Bone-Seeking Radiolabeled Compounds for Diagnosis and Therapy of Bone Metastases

Well-Designed Bone-Seeking Radiolabeled Compounds for Diagnosis and Therapy of Bone Metastases

Understanding the Progression of Bone Metastases to Identify Novel Therapeutic Targets

It is time to move forward into the era of Theranostics

Contact Info

Product

Resources

About